Skip to Content
Merck

Expression of polycomb targets predicts breast cancer prognosis.

Molecular and cellular biology (2013-08-07)
Alba Jene-Sanz, Renáta Váraljai, Alexandra V Vilkova, Galina F Khramtsova, Andrey I Khramtsov, Olufunmilayo I Olopade, Nuria Lopez-Bigas, Elizaveta V Benevolenskaya
ABSTRACT

Global changes in the epigenome are increasingly being appreciated as key events in cancer progression. The pathogenic role of enhancer of zeste homolog 2 (EZH2) has been connected to its histone 3 lysine 27 (H3K27) methyltransferase activity and gene repression; however, little is known about relationship of changes in expression of EZH2 target genes to cancer characteristics and patient prognosis. Here we show that through expression analysis of genomic regions with H3K27 trimethylation (H3K27me3) and EZH2 binding, breast cancer patients can be stratified into good and poor prognostic groups independent of known cancer gene signatures. The EZH2-bound regions were downregulated in tumors characterized by aggressive behavior, high expression of cell cycle genes, and low expression of developmental and cell adhesion genes. Depletion of EZH2 in breast cancer cells significantly increased expression of the top altered genes, decreased proliferation, and improved cell adhesion, indicating a critical role played by EZH2 in determining the cancer phenotype.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Vimentin antibody produced in mouse, clone VIM-13.2, ascites fluid
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
1 ea
Please contact Customer Service for Availability
€942.00
Sigma-Aldrich
Monoclonal Anti-α-Tubulin antibody produced in mouse, clone DM1A, ascites fluid
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
1 ea
Please contact Customer Service for Availability
€942.00